Sudeep Pharma IPO Review
Sudeep Pharma IPO has been reviewed by 3 analysts, and the overall consensus is Apply — carrying a score of 83. Out of the 3 analysts who have covered this IPO, 2 recommend subscribing while 1 advises caution or avoidance — reflecting a broadly positive view from the analyst community.
The issue is priced in the band of ₹563-593 per share, with a minimum application size of 25 shares (minimum investment of approximately ₹14,825 at the upper band). Subscription ran from 21 Nov 2025 to 25 Nov 2025. The issue size is ₹895 crore, a mix of fresh issue and offer for sale. Scroll down for the full analyst breakdown and analyst-wise verdicts.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Analyst verdict & score
One score out of 100, aggregated from every analyst verdict tracked for this issue. How it's calculated
Higher consensus indicates broader analyst agreement.
Detailed review
What the analyst reports say, grouped by the question you're likely asking.
General review
Sudeep Pharma IPO bidding started from Nov 21, 2025 and ended on Nov 25, 2025. The allotment for Sudeep Pharma IPO was finalized on Nov 26, 2025. Sudeep Pharma IPO will list on BSE, NSE with a tentative listing date fixed as Nov 28, 2025
Listing gains
Short-term strategy
Long-term strategy
How this is written: an AI-assisted summary of the 3 analyst reports listed below. It reports their views; IPO Guru does not make buy or sell recommendations.
Analyst reviews
Ordered by each analyst's track record over the past year; analysts still building one are listed last.
Latest IPO reviews
How analysts rated the most recent mainboard issues — and, where they have listed, how the call played out.
Frequently asked
Should I apply for Sudeep Pharma IPO?
The analyst consensus for Sudeep Pharma IPO tracked on this page is Apply, with a score of 83/100. Out of 3 analysts who have reviewed this IPO, 2 recommend subscribing. IPO Guru does not make buy or sell recommendations. Read the individual analyst reports and consult a SEBI-registered advisor before investing.
What does the score of 83 mean for Sudeep Pharma IPO?
The score of 83 is an aggregate of all analyst ratings tracked for Sudeep Pharma IPO. A score in this range indicates strong analyst confidence — most analysts are recommending a subscribe. Read the individual analyst verdicts above for more context.
What was the actual listing price of Sudeep Pharma IPO?
Sudeep Pharma IPO listed on November 28, 2025 at ₹730, against the issue price of ₹593 — a gain of +23.1% (₹137 per share). View the full GMP history page for day-wise pre-listing trends.
What is the price band and lot size of Sudeep Pharma IPO?
Sudeep Pharma IPO was priced at ₹563-593 per share. The minimum lot size is 25 shares, making the minimum investment approximately ₹14,825 at the upper end of the price band. Subscription ran from 21 Nov 2025 to 25 Nov 2025.
Explore Sudeep Pharma IPO further
Analyst views are one input. Read them alongside the demand, the grey market and the filings before you decide.
It has listed — go back to the fundamentals.
Live grey market premium, Kostak and Subject to Sauda, with the day-wise trend.
Category-wise demand from QIB, NII and retail investors, updated through the day.
Check with your PAN whether shares were credited to your demat account.
A verdict is an opinion, not a guarantee.
IPO Guru collects analyst views, GMP, subscription and allotment for every Mainboard and SME issue. Weigh them together — and against the offer document — before you apply.
Disclaimer: Grey Market Premium (GMP) is for information purposes and is not a guarantee of listing price. Always consult your financial advisor before investing.
